CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in cases of primary biliary cholangitis
3.4.1.2. Rise in research and development
3.4.2. Restraints
3.4.2.1. Lack of early diagnosis and limited treatment options
3.4.3. Opportunities
3.4.3.1. Rise in adoption of key strategies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Primary Drug
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Primary Drug Primary Biliary Cholangitis Therapeutics Market by Type
4.3. Secondary Drug
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital Pharmacies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Drugs Stores and Retail Pharmacies
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Online Pharmacies
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Drug type
6.2.3. Market size and forecast, by Distribution Channel
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Drug type
6.2.4.1.3. Market size and forecast, by Distribution Channel
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Drug type
6.2.4.2.3. Market size and forecast, by Distribution Channel
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Drug type
6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Drug type
6.3.3. Market size and forecast, by Distribution Channel
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Drug type
6.3.4.1.3. Market size and forecast, by Distribution Channel
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Drug type
6.3.4.2.3. Market size and forecast, by Distribution Channel
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Drug type
6.3.4.3.3. Market size and forecast, by Distribution Channel
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Drug type
6.3.4.4.3. Market size and forecast, by Distribution Channel
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Drug type
6.3.4.5.3. Market size and forecast, by Distribution Channel
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Drug type
6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Drug type
6.4.3. Market size and forecast, by Distribution Channel
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Drug type
6.4.4.1.3. Market size and forecast, by Distribution Channel
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Drug type
6.4.4.2.3. Market size and forecast, by Distribution Channel
6.4.4.3. Australia
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Drug type
6.4.4.3.3. Market size and forecast, by Distribution Channel
6.4.4.4. India
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Drug type
6.4.4.4.3. Market size and forecast, by Distribution Channel
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Drug type
6.4.4.5.3. Market size and forecast, by Distribution Channel
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Drug type
6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Drug type
6.5.3. Market size and forecast, by Distribution Channel
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Drug type
6.5.4.1.3. Market size and forecast, by Distribution Channel
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Drug type
6.5.4.2.3. Market size and forecast, by Distribution Channel
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Drug type
6.5.4.3.3. Market size and forecast, by Distribution Channel
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Drug type
6.5.4.4.3. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Intercept Pharmaceuticals, Inc.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Lupin
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Zydus Lifesciences Limited
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Sun Pharmaceutical Industries Ltd
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Leeford Healthcare Limited
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.6. Alkem Laboratories Ltd.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. AMAGEN INDIA LIFE SCIENCES
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.8. GENFIT
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Ipsen Pharma
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. ABC Farmaceutici S.p.a.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Key strategic moves and developments
TABLE 01. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL PRIMARY DRUG PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 06. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 10. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 13. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 14. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 16. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 18. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 20. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 23. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 27. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 29. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 31. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 37. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 40. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 42. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 53. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. INTERCEPT PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 61. INTERCEPT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 62. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 63. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 64. INTERCEPT PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 65. LUPIN: KEY EXECUTIVES
TABLE 66. LUPIN: COMPANY SNAPSHOT
TABLE 67. LUPIN: PRODUCT SEGMENTS
TABLE 68. LUPIN: PRODUCT PORTFOLIO
TABLE 69. LUPIN: KEY STRATERGIES
TABLE 70. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 71. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 72. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 73. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
TABLE 75. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 76. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 77. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 78. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 79. LEEFORD HEALTHCARE LIMITED: KEY EXECUTIVES
TABLE 80. LEEFORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
TABLE 81. LEEFORD HEALTHCARE LIMITED: PRODUCT SEGMENTS
TABLE 82. LEEFORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
TABLE 83. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 84. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 85. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 86. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 87. AMAGEN INDIA LIFE SCIENCES: KEY EXECUTIVES
TABLE 88. AMAGEN INDIA LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 89. AMAGEN INDIA LIFE SCIENCES: PRODUCT SEGMENTS
TABLE 90. AMAGEN INDIA LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 91. GENFIT: KEY EXECUTIVES
TABLE 92. GENFIT: COMPANY SNAPSHOT
TABLE 93. GENFIT: PRODUCT SEGMENTS
TABLE 94. GENFIT: PRODUCT PORTFOLIO
TABLE 95. GENFIT: KEY STRATERGIES
TABLE 96. IPSEN PHARMA: KEY EXECUTIVES
TABLE 97. IPSEN PHARMA: COMPANY SNAPSHOT
TABLE 98. IPSEN PHARMA: PRODUCT SEGMENTS
TABLE 99. IPSEN PHARMA: PRODUCT PORTFOLIO
TABLE 100. IPSEN PHARMA: KEY STRATERGIES
TABLE 101. ABC FARMACEUTICI S.P.A.: KEY EXECUTIVES
TABLE 102. ABC FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
TABLE 103. ABC FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
TABLE 104. ABC FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO
TABLE 105. ABC FARMACEUTICI S.P.A.: KEY STRATERGIES
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
